Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Delcath Systems Inc (DCTH)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Delcath Systems's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5.300 +0.040    +0.76%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
5.302
+0.002
+0.030%
22:57:35 - Real-time Data
  • Volume: 110,200
  • Bid/Ask: 5.300 / 5.380
  • Day's Range: 5.280 - 5.500
Type:  Equity
Market:  United States
Delcath Systems 5.300 +0.040 +0.76%

Delcath Systems Company Profile

 
Read the Delcath company profile to learn more about the business and the management team. View Delcath Systems Inc facts about employee data, company products and services, and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

52

Equity Type

ORD

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Contact Information

Address 1633 Broadway 22nd Floor
Suite C New York, 10019
United States
Phone 212 489 2100
Fax 212 489 2102

Top Executives

Name Age Since Title
John Richard Sylvester 57 2019 Independent Director
Gerard J. Michel 58 2020 CEO & Director
Gilad Aharon 47 2020 Independent Director
Roger G. Stoll 80 2008 Independent Director
Elizabeth Adkins Czerepak 67 2020 Independent Director
Steven A.J. Salamon - 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DCTH Price Commentary

Write your thoughts about Delcath Systems Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Wiktor Jespersen
Wiktor Jespersen Sep 21, 2017 15:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well dcth isnt known for rel news
Jimmy Nge
Jimmy Nge Sep 09, 2017 8:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RS result? Why no news at all
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email